The overall grade 3/4 AEs were similar in both groups (atezolizumab–bevacizumab: 57%; sorafenib: 55%), but hypertension (atezolizumab–bevacizumab: 15.2%; sorafenib: 12.2%), proteinuria (atezolizumab–bevacizumab: 3.0%; sorafenib: 0.6%), raised aspartate aminotransferase (AST) (atezolizumab–bevacizumab: 7.0%; sorafenib: 5.1%) and elevated alanine aminotransferase (ALT) (atezolizumab–bevacizumab: 3.6%; sorafenib: 1.3%) were more common with combination therapy [24]. The gene discussed is GPT; the disease is hypertensive disorder.